featured
Cadonilimab Plus Chemotherapy With or Without Bevacizumab as a First-Line Treatment for Recurrent or Metastatic Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Clin. Cancer Res 2024 Apr 15;30(8)1501-1508, H Lou, H Cai, X Huang, G Li, L Wang, F Liu, W Qin, T Liu, W Liu, ZM Wang, B Li, Y Xia, J WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.